Катрен Стиль28 февраля 2018
Выпуск: №169, февраль 20182897 просмотров
Array
(
[0] => Array
(
[ID] => 16466
[~ID] => 16466
[NAME] => apteka.ru/search/?q=%D1%81%D1%82%D0%B5%D0%BB%D0%BB%D0%B0%D0%BD%D0%B8%D0%BD&order=products%2Cmaterials&vendor=
[~NAME] => apteka.ru/search/?q=%D1%81%D1%82%D0%B5%D0%BB%D0%BB%D0%B0%D0%BD%D0%B8%D0%BD&order=products%2Cmaterials&vendor=
[DATE_ACTIVE_FROM] => 01.09.2019 11:17:00
[~DATE_ACTIVE_FROM] => 01.09.2019 11:17:00
[IBLOCK_ID] => 12
[~IBLOCK_ID] => 12
[PREVIEW_PICTURE] => 8171
[~PREVIEW_PICTURE] => 8171
)
[PROPERTIES] => Array
(
[SWF] => Array
(
[ID] => 99
[TIMESTAMP_X] => 2018-08-19 19:34:17
[IBLOCK_ID] => 12
[NAME] => Ссылка во флеше (link1)
[ACTIVE] => Y
[SORT] => 500
[CODE] => SWF
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => S
[ROW_COUNT] => 1
[COL_COUNT] => 50
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Ссылка во флеше (link1)
[~DEFAULT_VALUE] =>
)
[LINK] => Array
(
[ID] => 100
[TIMESTAMP_X] => 2018-08-19 19:34:17
[IBLOCK_ID] => 12
[NAME] => Ссылка (без протокола)
[ACTIVE] => Y
[SORT] => 500
[CODE] => LINK
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => S
[ROW_COUNT] => 1
[COL_COUNT] => 50
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] => 320465417
[VALUE] => apteka.ru/search/?q=%D0%B1%D0%B5%D1%80%D0%B5%D1%88&order=products%2Cmaterials&vendor=0
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] => apteka.ru/search/?q=%D0%B1%D0%B5%D1%80%D0%B5%D1%88&order=products%2Cmaterials&vendor=0
[~DESCRIPTION] =>
[~NAME] => Ссылка (без протокола)
[~DEFAULT_VALUE] =>
)
[WEBINARS] => Array
(
[ID] => 102
[TIMESTAMP_X] => 2020-11-05 08:23:57
[IBLOCK_ID] => 12
[NAME] => Вебинары
[ACTIVE] => Y
[SORT] => 500
[CODE] => WEBINARS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => E
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 5
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => Y
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] => EList
[USER_TYPE_SETTINGS] => Array
(
[size] => 20
[width] => 0
[group] => Y
[multiple] => Y
)
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Вебинары
[~DEFAULT_VALUE] =>
)
[TYPES] => Array
(
[ID] => 103
[TIMESTAMP_X] => 2018-08-20 03:08:52
[IBLOCK_ID] => 12
[NAME] => Где показывать
[ACTIVE] => Y
[SORT] => 500
[CODE] => TYPES
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => L
[ROW_COUNT] => 20
[COL_COUNT] => 30
[LIST_TYPE] => C
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => Y
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] => Array
(
[0] => 320482201
)
[VALUE] => Array
(
[0] => Страница статьи (273px)
)
[DESCRIPTION] => Array
(
[0] =>
)
[VALUE_ENUM] => Array
(
[0] => Страница статьи (273px)
)
[VALUE_XML_ID] => Array
(
[0] => ade3837e8e0b9a67adab1fec2bc57639
)
[VALUE_SORT] => Array
(
[0] => 500
)
[VALUE_ENUM_ID] => Array
(
[0] => 458
)
[~VALUE] => Array
(
[0] => Страница статьи (273px)
)
[~DESCRIPTION] => Array
(
[0] =>
)
[~NAME] => Где показывать
[~DEFAULT_VALUE] =>
)
[RUBRICS] => Array
(
[ID] => 104
[TIMESTAMP_X] => 2018-08-20 03:09:12
[IBLOCK_ID] => 12
[NAME] => Рубрики
[ACTIVE] => Y
[SORT] => 500
[CODE] => RUBRICS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => G
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 20
[TMP_ID] =>
[LINK_IBLOCK_ID] => 2
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => Y
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Рубрики
[~DEFAULT_VALUE] =>
)
[VIEWS] => Array
(
[ID] => 105
[TIMESTAMP_X] => 2018-08-19 23:38:24
[IBLOCK_ID] => 12
[NAME] => Показы
[ACTIVE] => Y
[SORT] => 500
[CODE] => VIEWS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => N
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Показы
[~DEFAULT_VALUE] =>
)
[CLICKS] => Array
(
[ID] => 106
[TIMESTAMP_X] => 2018-08-19 23:38:24
[IBLOCK_ID] => 12
[NAME] => Клики
[ACTIVE] => Y
[SORT] => 500
[CODE] => CLICKS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => N
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Клики
[~DEFAULT_VALUE] =>
)
[ARTICLE] => Array
(
[ID] => 116
[TIMESTAMP_X] => 2019-05-17 13:18:54
[IBLOCK_ID] => 12
[NAME] => Статьи
[ACTIVE] => Y
[SORT] => 500
[CODE] => ARTICLE
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => E
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 2
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] => EList
[USER_TYPE_SETTINGS] => Array
(
[size] => 20
[width] => 0
[group] => N
[multiple] => Y
)
[HINT] =>
[PROPERTY_VALUE_ID] => Array
(
[0] => 320482202
)
[VALUE] => Array
(
[0] => 32724
)
[DESCRIPTION] => Array
(
[0] =>
)
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] => Array
(
[0] => 32724
)
[~DESCRIPTION] => Array
(
[0] =>
)
[~NAME] => Статьи
[~DEFAULT_VALUE] =>
)
[CRIB] => Array
(
[ID] => 117
[TIMESTAMP_X] => 2019-05-30 07:53:16
[IBLOCK_ID] => 12
[NAME] => Шпаргалки
[ACTIVE] => Y
[SORT] => 500
[CODE] => CRIB
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => E
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 3
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] => EList
[USER_TYPE_SETTINGS] => Array
(
[size] => 20
[width] => 0
[group] => N
[multiple] => N
)
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Шпаргалки
[~DEFAULT_VALUE] =>
)
)
[1] => Array
(
[ID] => 15705
[~ID] => 15705
[NAME] => Стелланин апрель
[~NAME] => Стелланин апрель
[DATE_ACTIVE_FROM] => 01.04.2019 13:37:00
[~DATE_ACTIVE_FROM] => 01.04.2019 13:37:00
[IBLOCK_ID] => 12
[~IBLOCK_ID] => 12
[PREVIEW_PICTURE] => 7449
[~PREVIEW_PICTURE] => 7449
)
[2] => Array
(
[ID] => 32741
[~ID] => 32741
[NAME] => Береш Май Обзор писем РЗН
[~NAME] => Береш Май Обзор писем РЗН
[DATE_ACTIVE_FROM] => 28.05.2020 08:53:00
[~DATE_ACTIVE_FROM] => 28.05.2020 08:53:00
[IBLOCK_ID] => 12
[~IBLOCK_ID] => 12
[PREVIEW_PICTURE] => 10191
[~PREVIEW_PICTURE] => 10191
)
)
Аспирин может быть заменой дорогостоящему антикоагулянту
Канадские ученые из Института изучения здравоохранения (Canadian Institutes of Health Research) продемонстрировали возможность использовать аспирин как замену антикоагулянту ривароксабану при профилактике венозной тромбоэмболии. Статья об этом была опубликована 22 февраля в журнале New England Journal of Medicine.
В исследовании приняло участие 3424 человека, прошедших операции по восстановлению тазобедренных или коленных суставов. Все пациенты в течение 5 дней после операции принимали 10 мг ривароксабана, а затем были разделены на две группы. 1717 человек продолжили прием ривароксабана, другая часть пациентов (1707 человек) принимала 81 мг аспирина ежедневно.
После 90 дней наблюдений ученые зафиксировали 11 случаев венозной тромбоэмболии в группе, принимавшей аспирин, и 12 случаев у группы ривароксабана. Вероятность появления тромба составила 0,64 % при приеме аспирина и 0,70 % — при приеме ривароксабана. Обширное кровотечение было отмечено у 8 пациентов, принимавших аспирин (0,47 % от общего числа), и у 5 человек, принимавших ривароксабан (0,29 % от всех пациентов).
Учитывая низкую разницу в результатах, ученые пришли к выводу, что аспирин может служить заменой дорогостоящему ривароксабану при профилактике венозной тромбоэмболии. Авторы исследования отмечают, что понадобятся дополнительные исследования, прежде чем терапия аспирином может стать клинической рекомендацией.
2897 просмотров
Поделиться ссылкой с друзьями ВКонтакте Одноклассники
Нашли ошибку? Выделите текст и нажмите Ctrl+Enter.
зарегистрированным пользователям